This inventor holds 1 USPTO granted patent. Top assignee: Calliditas Therapeutics Suisse Sa. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Alastair Hodges: Innovator in NADPH Oxidase Inhibition
Introduction
Alastair Hodges is a notable inventor based in Cambridgeshire, GB. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that serve as inhibitors of NADPH oxidase. His work is crucial for advancing treatments for various disorders related to this enzyme.
Latest Patents
Hodges holds a patent for "Compounds as NADPH oxidase inhibitors." This patent discloses new compounds and their pharmaceutical compositions, which are intended for the treatment and/or prophylaxis of conditions associated with Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase). He has 1 patent to his name, showcasing his innovative approach to addressing health challenges.
Career Highlights
Alastair Hodges is currently associated with Calliditas Therapeutics Suisse SA, where he continues to work on groundbreaking research and development in the pharmaceutical sector. His expertise in the field has positioned him as a valuable asset to the company and the broader scientific community.
Conclusion
Alastair Hodges exemplifies the spirit of innovation in the pharmaceutical industry through his work on NADPH oxidase inhibitors. His contributions are paving the way for new therapeutic options and enhancing our understanding of related health conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile